Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
Madany E, Lee J, Halprin C, Seo J, Baca N, Majlessipour F, Hendrickson JE, Pepkowitz SH, Hayes C, Klapper E, Gibb DR. Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease. EJHaem 2021, 2: 700-710. PMID: 35128535, PMCID: PMC8813163, DOI: 10.1002/jha2.270.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsSickle cell diseaseCell diseaseRace-matched healthy controlsType 1 interferon responseFrequency of alloimmunizationNon-alloimmunized patientsBlood mononuclear cellsType 1 interferonExpression of ISGsGene scoreNonalloimmunized patientsRBC alloimmunizationPlasma cytokinesSCD patientsMononuclear cellsHealthy controlsHigh prevalenceBlood leukocytesAlloimmunizationViral immunityPatientsIFNISG expressionInterferon responsePotential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease
Madany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson JE, Gibb DR. Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers In Medicine 2021, 8: 679030. PMID: 34368185, PMCID: PMC8339405, DOI: 10.3389/fmed.2021.679030.Peer-Reviewed Original ResearchSickle cell diseaseCOVID-19 severityIFNα/βType 1 interferonCell diseaseSARS-CoV-2 infectionType 1 interferon responseCorona Virus Disease-19 (COVID-19) pandemicCohort of patientsMajority of patientsInterferon gene signatureIFNα/β productionRace-matched controlsDisease-19 pandemicCOVID-19Express elevated levelsMajority of evidenceSCD diseaseSevere sequelaeChronic inflammationFavorable outcomeVariable progressionClinical consequencesGeneral populationPatients